Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) shares crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $0.49 and traded as low as $0.4444. Humacyte shares last traded at $0.4450, with a volume of 5,769,439 shares trading hands.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on HUMA shares. Benchmark cut their target price on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research note on Thursday, August 13th. BTIG Research reiterated a “buy” rating and issued a $2.00 price target on shares of Humacyte in a research note on Tuesday, November 10th. Cantor Fitzgerald set a $1.00 price target on Humacyte in a research note on Thursday, November 12th. Williams Trading set a $1.00 price target on Humacyte in a report on Friday, October 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Friday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $4.48.
Read Our Latest Stock Report on HUMA
Humacyte Trading Down 18.0%
The company has a market cap of $123.62 million, a P/E ratio of -1.01 and a beta of 2.64. The firm’s 50 day moving average is $0.49 and its two-hundred day moving average is $0.77. The company has a quick ratio of 3.11, a current ratio of 3.34 and a debt-to-equity ratio of 3.65.
Hedge Funds Weigh In On Humacyte
Several hedge funds and other institutional investors have recently bought and sold shares of HUMA. Beacon Pointe Advisors LLC bought a new stake in Humacyte during the second quarter valued at $28,000. Bank of New York Mellon Corp bought a new position in shares of Humacyte in the 2nd quarter worth about $44,000. Sei Investments Co. bought a new position in shares of Humacyte in the 1st quarter worth about $56,000. Miramontes Capital LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at about $85,000. Finally, LaSalle St. Investment Advisors LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at about $89,000. Institutional investors and hedge funds own 44.71% of the company’s stock.
Humacyte Company Profile
Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.
Featured Stories
- Five stocks we like better than Humacyte
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
